Drugmakers Pfizer and Wyeth were closing in on a deal worth US$68 billion that could be announced before the markets opened yesterday, published reports said.
The New York Times and Wall Street Journal reported on Sunday evening that Pfizer, the maker of Lipitor and Viagra, was working to finish financing for the deal, the biggest US merger in three years.
The companies’ boards met on Sunday to consider the bid, people familiar with the talks said. Wyeth shareholders would get US$50.19 a share, including US$33 in cash and 0.985 Pfizer shares, one of the people said. That is a 29 percent premium to Wyeth’s price on Thursday, before the talks became public.
Pfizer chief executive officer Jeffrey Kindler, 53, would lead the combined company, two people said.
Sources at Pfizer could not be immediately reached for comment. A Wyeth spokesman said the company had no comment.
A deal would increase Pfizer’s revenue by half and add strength in biotech drugs, vaccines and over-the-counter products, including the Advil and Robitussin brands.
A deal would help Pfizer cushion itself against a steep revenue decline expected over the next several years as Lipitor, the world’s best-selling drug, and other major products lost patent protection.
The drugmaker is expected to lose billions of dollars in sales to cheaper generics.
Acquiring Wyeth would transform Pfizer from a pure pharmaceutical company into a broadly diversified health care giant, given Wyeth’s huge presence in biotech drugs, vaccines including the blockbuster pneumococcal vaccine Prevnar, veterinary medicines and consumer health products.
Biotech drugs, produced in living cells, are seen as hot commodities because they generally command high prices and have little to no risk of generic competition. Wyeth’s offerings include blockbuster rheumatoid arthritis drug Enbrel (sold jointly with Amgen Inc), and hemophilia treatments Refacto, BeneFIX and Xyntha.
A business combination would also allow the merged companies to slash costs with another round of job cuts in areas with significant overlap, from administration to research to sales.
The deal would be the largest acquisition in the drug industry since Pfizer bought Warner-Lambert Co for US$93.4 billion in 2000, the Journal reported.
Pfizer’s annual sales would rise 46 percent to about US$70 billion. That would help the New York-based company offset some of the US$12 billion in revenue it begins losing in 2011, when Pfizer’s top-selling Lipitor cholesterol pill faces generic competition.
The US$50.19-a-share price values the transaction at US$66.8 billion for Wyeth’s outstanding shares as of Oct. 31. The figure will be slightly higher when Wyeth employee stock options are converted into stock when the transaction is completed.
Investors gave the transaction an early vote of confidence. Pfizer’s shares rose US$0.24, or 1.4 percent, to US$17.45 on Friday when the talks were first reported by the Journal. Wyeth jumped 12.7 percent, or US$4.91, to US$43.74.
The combined company would have 130,000 employees, and its annual revenue would be 55 percent more than the world’s second-biggest drugmaker, London-based GlaxoSmithKline PLC, which has said it will focus on smaller purchases in the year ahead.
A Pfizer-Wyeth agreement would exceed Roche Holding AG’s US$43.7 billion offer for the remainder of Genentech Inc, announced in July.
The Wyeth transaction carries both promise and peril for Pfizer, analysts and investors said in interviews since talks were first reported by the Journal.
It could keep Pfizer’s earnings unchanged at US$2.69 a share from 2010 to 2015, when patents expire on some of Pfizer’s biggest products, said Tim Anderson, an analyst with Sanford C. Bernstein in New York, in a research report. That compares with a 68 percent drop without the acquisition, to US$1.40 in 2015.
To achieve that, Pfizer would need to cut 70 percent of Wyeth’s research, marketing and administrative costs, Anderson said.
Intel Corp chief executive officer Lip-Bu Tan (陳立武) is expected to meet with Taiwanese suppliers next month in conjunction with the opening of the Computex Taipei trade show, supply chain sources said on Monday. The visit, the first for Tan to Taiwan since assuming his new post last month, would be aimed at enhancing Intel’s ties with suppliers in Taiwan as he attempts to help turn around the struggling US chipmaker, the sources said. Tan is to hold a banquet to celebrate Intel’s 40-year presence in Taiwan before Computex opens on May 20 and invite dozens of Taiwanese suppliers to exchange views
Application-specific integrated circuit designer Faraday Technology Corp (智原) yesterday said that although revenue this quarter would decline 30 percent from last quarter, it retained its full-year forecast of revenue growth of 100 percent. The company attributed the quarterly drop to a slowdown in customers’ production of chips using Faraday’s advanced packaging technology. The company is still confident about its revenue growth this year, given its strong “design-win” — or the projects it won to help customers design their chips, Faraday president Steve Wang (王國雍) told an online earnings conference. “The design-win this year is better than we expected. We believe we will win
Power supply and electronic components maker Delta Electronics Inc (台達電) yesterday said it plans to ship its new 1 megawatt charging systems for electric trucks and buses in the first half of next year at the earliest. The new charging piles, which deliver up to 1 megawatt of charging power, are designed for heavy-duty electric vehicles, and support a maximum current of 1,500 amperes and output of 1,250 volts, Delta said in a news release. “If everything goes smoothly, we could begin shipping those new charging systems as early as in the first half of next year,” a company official said. The new
SK Hynix Inc warned of increased volatility in the second half of this year despite resilient demand for artificial intelligence (AI) memory chips from big tech providers, reflecting the uncertainty surrounding US tariffs. The company reported a better-than-projected 158 percent jump in March-quarter operating income, propelled in part by stockpiling ahead of US President Donald Trump’s tariffs. SK Hynix stuck with a forecast for a doubling in demand for the high-bandwidth memory (HBM) essential to Nvidia Corp’s AI accelerators, which in turn drive giant data centers built by the likes of Microsoft Corp and Amazon.com Inc. That SK Hynix is maintaining its